Study on the adverse effects affecting treatment outcome in smear positive tuberculosis patients under DOTS in Amritsar city
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20180272Keywords:
Tuberculosis, Adverse drug reactions, Treatment outcome, DOTSAbstract
Background: The world adopts DOTS strategy for TB control thought the national TB control programs in different countries and is making good progress. Despite the positive therapeutic effects, studies have shown that utilization of multidrug regimens can cause undesirable adverse drug reactions (ADRs) of varying degrees of severity, such as hepatotoxicity, gastrointestinal disorders, allergic reactions, arthralgia, neurological disorders and non-adherence to treatment as well.
Methods: The study was conducted on new smear positive patients registered under DOTS in two Treatment Units (TUs) present in Amritsar city. The prevalence of various adverse effects like gastro-intestinal, hepato-biliary, visual disturbances, musculoskeletal, skin and appendages, peripheral nervous system, etc was recorded and their effect on the outcome was observed. Data management and analysis was done by using Microsoft excel and SPSS version 17.00.
Results: Out of 250 patients, 149 (59.6%) were males and 101(40.4%) were females. Out of the total 250 cases, adverse effects were present in 44.4% cases. Most common adverse effects observed were gastrointestinal in 63.9% followed by fever and chills in 28.8% of cases.
Conclusions: On statistical analysis, it was observed that the absence of adverse effects was significantly associated with the favourable outcome (p<0.001).
Metrics
References
World Health Organization. WHO Report. Global tuberculosis control: epidemiology, strategy, financing. WHO/HTM/ TB/2008.393. Geneva, Switzerland: WHO, 2008.
World Health Organization. An expanded DOTS framework for effective tuberculosis control. Stop TB Communicable Diseases. Geneva: WHO Press. 2002: 1–20.
Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, et al. Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara. J Pak Med Assoc. 2008;58:531–6.
Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, Damrifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026–30.
Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ. 2008;86:B–D.
Bronner LE, Podewils LJ, Peters A, Somnath P, Nshuti L, Van der Walt M, et al. Impact of community tracer teams on treatment outcomes among tuberculosis patients in South Africa. BMC Public Health. 2012;12:621.
Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 2004;4:68.
Maciel EL, Guidoni LM, Favero JL, Hadad DJ, Molino LP, Jonhson JL, et al. Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health. J Brasileiro de Pneumologia. 2010;36:232–8.
Central TB Division (CTB). Managing the Revised National Tuberculosis Programme in your area: A training course. In: Module 1- 9. Central TB Division; Directorate General of Health Services, MOH&FW; 2005.
Vasankari T, Holmstrom P, Ollgren J, Lippo K, Kokki M, Ruutu P. Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study. BMC Public Health. 2007;7:291.
Mukherjee A, Singla R, Saha I. Comparing outcomes in new pulmonary sputum positive and sputum negative cases under RNTCP in rural India. Indian J Tuberc. 2009;56:144-50.
Chennaveerappa PK, Siddharam SM, Halesha BR, Vittal BG, Jayashree N. Treatment outcome of tuberculosis patients registered at DOTS centre in a teaching hospital, South India. Int J Biol Med Res. 2011;2:487-9.
Aggarwal SS, Aggarwal NS, Makadia BK, Nagar SS. Assessment of one year of RNTCP. Indian J Comm Med. 2004;4:164-5.
Mishra A, Mishra S, Chouksey M, Gautam P, Verma P, Srivastava D, et al. A study of effectiveness of DOTS on tuberculosis patients treated under RNTCP programme. NTI Bulletin. 2007;43:47-50.
Verma V, Singh J, Chand N, Khalsa JS. Treatment outcome of tuberculosis under DOTS in patients presenting at Chest and TB Hospital, Amritsar. CHEST. 2005;128(4):403S.
Verma SK, Verma Sanjay K, Kant S, Kumar S, Prasad R. A five year follow up of Revised National Tuberculosis Control Programme of India at Lucknow. Indian J Chest Dis Allied Sci. 2008;50:195-8.
TB India. 2011. Revised National Tuberculosis Control Programme. Annual Status Report: TB India 2011. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2010. Available at: http://www. tbcindia.org/pdfs/RNTCP%20TB%20India%202011.pdf. Accessed on 3 June 2011.
Mittal C, Gupta SC. Noncompliance to DOTS: How it can be decreased. Indian J Comm Med. 2011;36:27-30.
Pandit N, Choudhary SK. A study on treatment compliance in Directly Observed Therapy for tuberculosis. Indian J Comm Med. 2006;31(4):241-3.
Downloads
Published
How to Cite
Issue
Section
